De Novo Design of an Androgen Receptor DNA Binding Domain-Targeted Peptide PROTAC for Prostate Cancer Therapy

The authors designed a novel peptide-based proteolysis-targeting chimera drug to induce androgen receptor and androgen receptor splice variant-7 degradation in a DNA binding domain and MDM2-dependent manner.